Cargando…
Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles
Effective systemic treatment for hepatocellular carcinoma (HCC) remains urgently needed. Sorafenib is the first FDA-approved systemic treatment for HCC. However, individual HCC patents’ response to sorafenib varies greatly. How to enhance the anti-HCC effect of sorafenib is still a significant chall...
Autores principales: | Song, Chenghua, Zhang, Jia, Wen, Ruichao, Li, Qingshan, Zhou, Jiaxuan, Xiaoli liu, Wu, Zheng, Lv, Yi, Wu, Rongqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287642/ https://www.ncbi.nlm.nih.gov/pubmed/35856043 http://dx.doi.org/10.1016/j.mtbio.2022.100350 |
Ejemplares similares
-
Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor
por: Hajihassan, Zahra, et al.
Publicado: (2023) -
Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells
por: Jafari, Reza, et al.
Publicado: (2019) -
Microtissues from mesenchymal stem cells and siRNA-loaded cross-linked gelatin microparticles for bone regeneration
por: Hinkelmann, Sandra, et al.
Publicado: (2021) -
Src siRNA prevents corticosteroid-associated osteoporosis in a rabbit model
por: Zheng, Li-Zhen, et al.
Publicado: (2016) -
Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer
por: Xu, Xinzhi, et al.
Publicado: (2022)